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ABSTRACT 
Introduction: In adults, muscle disease (MD) is most often a chronic long term condition with no 
definitive cure. It causes wasting and weakness of the muscles resulting in a progressive decline in mobility, 
alongside other symptoms, and is typically associated with reduced quality of life (QoL). Previous research 
suggests that a psychological intervention, and in particular Acceptance and Commitment Therapy (ACT), 
may help improve QoL in MD. ACT is a newer type of cognitive behavioural treatment that aims to improve 
QoL by virtue of improvement in a process called psychological flexibility. The primary aim of this 
randomised control trial (RCT) is to evaluate the efficacy of a guided self-help ACT programme for 
improving QoL in people with MD. Main secondary outcomes are mood, symptom impact, work and social 
adjustment and function at 9-week follow-up. 
Methods and analysis: ACTMuS is an assessor-blind, multicentre, two-armed, parallel-group RCT to 
assess the efficacy of ACT plus standard medical care (SMC) compared to SMC alone. Individuals with a 
diagnosis of one of four specific MDs, with a duration of at least 6 months, and with mild to moderate 
anxiety or depression (HADS score ≥ 8) will be recruited from UK-based MD clinics and MD patient 
support organisations. Participants will be randomised to either ACT plus SMC or SMC alone by an 
independent randomisation service. Participants will be followed up at 3, 6 and 9 weeks. Analysis will be 
intention to treat, conducted by the trial statistician who will be blinded to treatment allocation.  
Ethics and dissemination: The study has received full ethical approval. Study results will be 
disseminated via peer-reviewed publications, conference presentations and journal articles. Data obtained 
from the trial will enable clinicians and health service providers to make informed decisions regarding the 
efficacy of ACT for improving QoL for patients with MD.  
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STRENGTHS AND LIMITATIONS OF THIS STUDY: 
• ACTMuS is the first randomised controlled trial to test the efficacy of an ACT-informed intervention 
for MDs against standard medical care (SMC).  
• To our knowledge this is the largest trial of a psychological intervention for MD, and the first that 
primarily targets QoL.  
• In order to improve access and increase uptake, the intervention is brief and designed to be delivered 
remotely (via e-mail and telephone). 
• Only a short follow-up period was included and consequently this study will not be able to 
investigate longer-term treatment effects. An intrinsic limitation to the study is the lack of 
comparable therapist’s time and attention within the SMC alone group. 
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INTRODUCTION 
Background and rationale 
Muscle diseases (MDs) are a group of primary disorders of the muscle, the majority of which are chronic and 
progressive. They affect approximately over 70,000 people (children and adults) in the UK (1). The 
diagnosis of a specific MD is based on several criteria including the pattern of the muscle weakness, the 
muscle biopsy appearances and in some cases genetic testing. Four MDs, namely limb girdle muscular 
dystrophy (LGMD), Becker’s muscular dystrophy (BMD) (dystrophin deficiency), facioscapulohumeral 
muscular dystrophy (FSHD), and inclusion body myositis (IBM) comprise a significant proportion of those 
seen in an adult muscle clinic. They are characterised by progressive limb muscle wasting and weakness that 
cause difficulties with mobility and physical functioning. Some MDs also involve bulbar muscles causing 
dysphagia, respiratory muscles causing respiratory compromise, and cardic muscle causing cardiac 
symptoms. As well as weakness, commonly reported symptoms include chronic pain, sleep disturbance and 
fatigue (2, 3). Unlike some MDs these four MDs do not have additional multi-system or central nervous 
system involvement. At present most MDs are without disease-modifying treatments or cures.  
Typically people with MD report reduced quality of life (QoL) and may experience increased levels of 
anxiety and depression (4, 5). A systematic review of 26 studies highlighted that, compared to controls, 
people with MD had compromised QoL in all areas of functioning (5). The degree of physical disability is a 
determinant of QoL in MDs (5). Therefore, clinical treatment is often directed at maintaining physical 
functioning. For example, physiotherapy and occupational therapy are applied to maximise remaining 
muscle function and patients are monitored for any cardiac or respiratory problems that may need supportive 
treatment. Even so, such interventions may have ability to improve QoL to a degree. 
However,physical disability does not explain all the variance in QoL (4, 6, 7). Psychological variables such 
as illness beliefs (6, 8), coping methods (9-11) and psychological flexibility (12) have been shown to account 
for variance in QoL. These findings are in line with a biopsychosocial model (13) where QoL is theorised to 
depend upon the interaction of psychological factors with biological and social factors.   
The relationship between QoL and psychosocial factors in MD provides a treatment opportunity. In the 
absence of a direct cure for MD, psychological interventions may offer a way to enhance QoL. 
Encouragingly, a recent small RCT of a traditional cognitive behavioural intervention for improving fatigue 
in FSHD showed a beneficial effect on fatigue and QoL (14). 
Acceptance and Commitment Therapy (ACT) 
Dependent on treatment aims, several types of psychological interventions may be helpful for people with 
MD (15). ACT is a newer form of cognitive-behavioural approach that focuses on improving a process called 
psychological flexibility (16). Psychological flexibility is “[…] the capacity to persist or to change behaviour 
in a way that includes conscious and open contact with thoughts and feelings, appreciates what the situation 
affords, and serves one’s goals and values” (17). In observational studies psychological flexibility has been 
shown to be predictive of positive outcomes (QoL, mood) and better functioning across a range of 
challenging contexts, such as living with chronic illness and chronic pain. A 4-month prospective 
observational study with a group of people with MD observed that psychological flexibility was predictive of 
change in life satisfaction and anxiety (18). 
Given its focus on improving psychological flexibility, ACT may prove beneficial for those with MD. In 
ACT a number of treatment techniques are used to improve psychological flexibility including therapist 
interaction, mindfulness and functional analysis. These aim to: a) help individuals become more aware of 
thoughts and feelings and their relationship to, in this case, their MD; b) broaden the range of behaviours 
(often to include open and willing responses) that can be applied when in the presence of difficult thoughts 
and feelings; c) help them to flexibly choose those behaviours that help them to make progress on their over-
arching goals and values.  
Several recent meta-analyses have suggested that ACT is an efficacious treatment for improving mood and 
QoL in mental health conditions (19, 20) and chronic pain (21). In chronic diseases there is a growing 
evidence base (12), with encouraging results for trials with cancer (22), diabetes (23), and epilepsy (24) 
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populations.  However, to date, most studies of ACT for chronic diseases have been of a preliminary nature 
(i.e. small, uncontrolled, and/or lower quality (12). Thus, adequately-powered, rigorous evaluation of ACT 
for improving QoL in chronic diseases will be a helpful addition to the literature.  
The selection of a guided self-help approach 
The one comprehensive trial of a psychological intervention in MD (14) tested the efficacy of a 16 session 
traditional cognitive behavioural therapy for improving fatigue. While results were encouraging, both on 
fatigue and secondary outcomes such as QoL and mood, for several reasons (including the time spent 
travelling) uptake was low, and a proportion (24%) struggled to achieve even a minimal level of adherence 
to the intervention. This suggests that issues, perhaps mobility difficulties and treatment length, may hinder 
face-to-face treatment options for many with MD. A further problem with the development and 
implementation of any new treatment concerns the resource limitations common to many health service 
providers, including the NHS in the UK.  
A practical solution to this problem could be the implementation of an intervention delivered remotely 
through online and computerised self-guided resources aided by telephone or video calls. Such methods of 
delivery are increasingly feasible given that the majority of UK households now have web access. Also 
recent systematic reviews suggest that promising results can be obtained from web-based interventions for 
adults with chronic illnesses and depression (25-27). Web based interventions not only remove the burden of 
travel, but also allows the completion of material at a convenient place, time, and pace. Remotely delivered 
interventions can be a cost-effective approach for providing treatment increasing its chances of wider 
implementation.  
Given the potential benefits of using ACT within an MD population, and taking into account potential 
barriers to participation, we developed,for this population,a brief self-guided intervention that can be 
supported remotely via e-mail and telephone contact with a therapist. We assessed this in a preliminary 
multiple-baseline case series with seven participants (28). The results of this case series suggested that such 
an approach was practicable and acceptable and that mood and QoL might respond to this treatment. Given 
this promising evaluation we plan to conduct a randomised controlled trial, to evaluate the efficacy of this 
intervention for improving QoL in people living with MD. 
This protocol describes a multicentre, two-armed, parallel-group RCT to assess the efficacy of self-guided 
ACT in improving QoL in individuals with MDs. A total of 154 people referred from MD clinics, Muscular 
Dystrophy UK and specific MD registries will be randomly allocated to receive either self-guided ACT plus 
standard medical care (SMC) or SMC alone. We hypothesise that the group who receive self-guided ACT 
plus SMC will report an improved QoL at the primary end point of 9 weeks follow-up compared with those 
receiving SMC alone.  
Objectives 
Primary objective: 
1) The primary objective is to evaluate the efficacy of ACT plus SMC on QoL compared to SMC alone 
at 9-weeks.  
Secondary objectives: 
1) To evaluate the impact of ACT plus SMC compared to SMC alone on secondary outcomes: mood, 
symptom impact domains, work and social adjustment and function at 9-week follow-up.  
2) To assess the processes that may be responsible for mediating the treatment effect. 
3) To evaluate participants’ views of the intervention and factors that act as facilitators and barriers to 
participation via a nested qualitative study.  
 
Trial Design  
ACTMuS is an assessor-blind, multicentre, two-armed, parallel-group randomised controlled trial (RCT) 
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METHODS: PARTICIPANTS, INTERVENTIONS AND OUTCOMES 
Setting  
A total of 154 participants will be recruited from UK National Health Service MD clinics, Muscular 
Dystrophy UK (MD-UK) and 3 disease-specific registries (FSHD, dysferlin, IBM). After obtaining consent, 
the baseline assessments will take place in MD clinics at King’s College Hospital (NHS Foundation Hospital 
Trust), The Royal London Hospital (Barts Health NHS Trust) and University Hospital Southampton (NHS 
Foundation Trust). The remainder of the study including treatment will be conducted remotely via email, 
telephone or video calls.  
Eligibility criteria   
Inclusion criteria 
1) Adults (aged 18 years and over) diagnosed with one of the following MDs that has been present for 
greater than 6 months: 
a. One of the limb girdle muscular dystrophies (LGMD) genetically or biopsy proven, 
b. Becker’ muscular dystrophy (BMD) (dystrophin deficiency) with biopsy or genetic diagnosis, 
c. Facioscapulohumeral muscular dystrophy (FSHD) diagnosed clinically with specific genetic 
abnormality in the subject or their family, 
d. Inclusion body myositis (IBM) clinic-pathologically defined, clinically defined or probable 
IBM based on European Neuromuscular Centre ENMC research diagnostic criteria 2013 (29).  
2) Potential participants must have access to the Internet and a computer to receive the study materials 
3)  HADS score of ≥ 8 for depression or ≥8 for anxiety.  
 
Exclusion criteria 
1) Unstable complications of MDs including neuromuscular respiratory weakness or cardiomyopathy.  
2) Major active co-morbidities unrelated to MD (such as arthritis, respiratory disease, cardiovascular 
disease).  
3) Current diagnosis of an active major mental health disorder likely to interfere with participation     
4) Current or recent participation in other treatment intervention studies (< 4 weeks after completion).  
5) Currently receiving psychological support or psychotherapy. 
6) Inability to read English questionnaires  
7) Cognitive impairment that would prevent comprehension of ACT modules and questionnaires (as 
assessed by the Montreal Cognitive Assessment 5-minute protocol, (30)). 
INTERVENTIONS 
Acceptance and Commitment Therapy 
The intervention is a remotely supported, guided self-help ACT programme (developed mainly by CG and 
LM, informed by other sources (16, 22, 31). It consists of four modules and corresponding audio files 
supported by five telephone support sessions with the trial therapist (Table 1). The first three modules are 
expected to take the participant 1 hour 30 minutes each and the final module 45 minutes to complete. This 
includes time to read the modules, listen to the audio files and work through tasks and exercises. During the 
first call, prior to receiving the first module (either by telephone or video call), the therapist will provide a 
15-minute introduction then email the first module. The subsequent three phone calls will each last 30-
minutes and will be followed by the next module. The telephone sessions provide participants with a chance 
to discuss the modules they have read, including their experiences of the exercises, and receive help with 
difficulties encountered. A 15-minute phone call will follow the final module to conclude the treatment.  
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Table 1 Summary of ACT modules 
 
The Clinical Psychologist delivering the ACT support sessions will attend a three-day training session prior 
to the start of recruitment. The first day will cover the rationale behind the study and insights into MD 
diagnosis, symptoms and impact on QoL (led by MR, a Consultant Neurologist). Details of the study 
protocol will be reviewed as well as the role of the therapist, standard operating procedures, recording and 
storage of the support sessions and confidential information, deviations, dropouts and adverse event 
procedures (led by TC, Professor of Cognitive Behaviour Therapy). The ACT training including 
presentations, exercises and role-plays will last 2 days. This will be led by LM, a Clinical Psychologist and 
expert in ACT, assisted by CG, an ACT-trained Clinical Psychologist. Obstacles to patient engagement with 
ACT as well as the difficulties of delivering the sessions remotely and within a brief time frame will be 
discussed. The therapist will attend monthly supervision meetings with a clinical supervisor (LM) to develop 
their skills and to ensure therapy fidelity and adherence to trial protocol. The therapist’s treatment 
competence will be periodically assessed with an ACT-fidelity scale. This will inform monthly supervision 
sessions between therapist and clinical supervisor throughout the trial. 
Treatment fidelity  
All ACT support sessions will be audio-recorded to assess treatment fidelity. At the end of the trial a random 
sample of recordings will be analysed for overall fidelity by two independent researchers. A fidelity measure 
is currently being developed by CG and LM. This comprises a basic therapeutic competence scale and an 
ACT-specific fidelity scale (ACT-FS) informed by guidelines provided by Plumb and Vilardaga (32). 
 
Module 1: 
Mindfulness and 
unhooking 
• Normalising difficult thoughts and feelings, given the context of MD, and 
associated struggles.  
• Discussion of consequences from trying to get rid of unwanted thoughts and 
feelings and opportunities for alternative responses. 
• Introducing other ways to interact with unwanted thoughts and feelings: 
1. Mindfulness or learning to be present in the moment and experience 
thoughts and feelings in a non-judgemental way.  
2. Unhooking from thoughts or learning ways to step-back from thoughts 
that often restrict actions or lead to avoidance. 
• Homework 1: Daily diary of mindfulness practice. 
• Homework 2: Identifying where one struggles and experimenting with other 
responses. 
Module 2: Follow 
your values 
• Identifying values and ways to pursue them with MD. Exploring the link 
between difficult thoughts and feelings and one’s goals and values.  
• Homework 1: Continuation of daily mindfulness practice 
• Homework 2: Setting goals in the context of values, experimenting with 
taking the ‘smallest possible step’ which is consistent with ones values, 
noticing the thoughts and feelings that occur in the context of values activity. 
Module 3: Take an 
observer perspective 
• Experimenting with taking an observer perspective on one’s experiences. 
• Considering labels one attaches to oneself (especially given the context of 
MD). Noticing a choice over buying into labels, and the impact of labels over 
one’s behaviour. 
• Introducing a more flexible approach to mindfulness 
• Homework 1: Continuation of daily mindfulness practice with addition of 
flexible attention and noticing the observer self  
• Homework 2: Continuation of valued activities   
Module 4: Recap, 
reflection and 
suggestions for 
staying committed  
• Review of homework tasks and skills learnt.  
• Self-identification of effective and ineffective behaviour patterns.   
• Goal planning and normalisation of set-backs with a compassionate approach 
to getting back on track. 
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Standard Medical Care (SMC) 
All participants will receive SMC, which involves the continuation of any current medical practices (without 
any psychological therapy). Standard medical care would be 1) review of functional impairment arising from 
their muscle weakness and measures suggested to ameliorate the resulting disability with home adaptations 
and assistive devices, 2) monitoring for respiratory or cardiac complications and appropriate referral for their 
management if required, 3) recommendations for local physiotherapy, 4) recommendations for falls 
management where appropriate, 5) answering queries about their condition usually using information leaflets 
from the national organisation Muscular Dystrophy UK or from disease support groups.   
 
Baseline measures  
Participants will complete baseline questionnaires (see Table 2) at the MD clinics with the research 
assistant (RA) and objective assessments with a physiotherapist. Participants will also complete a 
participant details form to provide demographic data as follows: age, gender, ethnicity, occupation 
status, education level, marital status, living arrangements and dependants. Clinical information will also 
be collected, including age of onset and duration of MD, additional diagnoses, experience of 
psychological therapies as well as prior treatment of anxiety or depression. Adverse events will be 
recorded at each assessment point of the trial.   
 
The objective assessments conducted by physiotherapists at baseline are as follows:  
 
• Adult Ambulatory Neuromuscular Assessment (ANA) is an adult version of the North Star Ambulatory 
Assessment (33) that measures motor function. Items are scored from 0-2, with an overall possible range 
of scores from 0-34. The higher the score, the better the patient can function. An additional item of the 
ANA that shall be used is the 6-minute timed walk test (6MTWT) which measures mobility by counting 
the distance walked within a 6-minute time-frame along with pauses or stops before the time is complete. 
The higher the score the greater the function of the patient.  
 
• Manual Muscle Strength Testing (MMST; aka Manual Muscle Testing, MMT) measures the strength of 
12 different muscles on both right and left from 0-5 (no contraction palpable – normal strength). There is 
a total possible range of scores from 0- 120, with higher scores representing levels of strength closest to 
normal levels (34).  
 
Outcome measures 
The RA blind to participant allocation will be responsible for ensuring outcome measures are completed at 3, 
6 and 9 weeks by all participants. The link to the measures will be sent to participants via email. If 
participants do not complete the questionnaires by the due date they will be reminded by the RA. All time 
points will be taken into account during analysis but the primary efficacy end-point is the 9-week follow-up. 
 
Primary outcome:  
• The Individualised Neuromuscular Quality of Life Questionnaire (INQoL) – life area domains (section 
2) is the primary outcome. The INQoL is a 10-domain, validated MD specific questionnaire to measure 
QoL (35). We will exclude the one domain that addresses the symptom of mytonia as none of the MDs 
being recruited has this symptom. This will leave 9 domains for the purpose of this study. The primary 
outcome of this study constitutes section 2 of the INQOL which assesses 5 life area domains (activities, 
independence, social functioning, emotional functioning & body image). Participants respond using a 7-
point Likert scale, with higher scores indicating greater symptom impact. The primary outcome measure 
for this study will therefore be the change in the overall QoL score, derived from these five life domain 
scores, from baseline up to 9-weeks.  
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Secondary outcome measures: 
 
• Individualised Neuromuscular Quality of Life Questionnaire (INQoL) symptom impact domains. This 
refers to categories within Section 1 of the INQoL (weakness, pain, tiredness) and follows the same 
format as described above. 
 
• Work and Social Adjustment Scale (WSAS) is a measure of impairment at work, home and social 
functioning (36). The total score comprises the sum of responses to five questions, each of which is on a 
nine-point Likert scale. The possible range of scores is 0-40; with higher scores indicating more greatly 
impaired daily functioning. 
 
• Hospital Anxiety and Depression Scale (HADS) is a self-report questionnaire to measure mood (37). It 
consists of fourteen items, relating to depression (7 items) and anxiety (7 items). Higher scores indicate 
either greater anxiety or depression. Each of the items are rated from 0-3 thus the possible range of 
scores for each is 0-21, with a cut-off of 8 showing good sensitivity and specificity for possible cases 
(38). 
 
• Stanford Health Assessment Questionnaire Disability Index (HAQ-DI) is a measure of functional 
impairment and level of disability (39).There are different ways to score the HAQ-DI. As with previous 
studies with MD populations (18) the alternative scoring method shall be used which focuses on 
measuring disability not adaption by not incorporating use of aids and devices. The measure includes 
eight activity domains (dressing, arising, eating, walking, hygiene, reach, grip, and activities). There are 
20 questions in total, each scored from 0-3. All the domains are summed for a total score with a higher 
score representing a greater impairment in ability to function in daily life. As additional measure of 
functional impairment, not treated as an efficacy outcome in the analysis, the IBM Functional Rating 
Scale (40) will be completed only by those participants with a diagnosis of Inclusion Body Myositis. 
This is a 10-point functional rating scale, with higher scores depicting greater functional impairment.  
 
• Patient Global Impression of Change scale (PGIC) is a single item measure of a patient’s impression of 
change over the study (41). Participants rate their impression of change on a scale of 1–7 as follows: 
‘very much better’, ‘much better’, ‘a little better’, ‘about the same’, ‘a little worse’, ‘much worse’ and 
‘very much worse’. 
 
• Rating of satisfaction is a single item measure of a patient’s satisfaction with the outcome of the trial. 
Participants rate their satisfaction on a scale of 1–7 as follows: ‘very satisfied’, ‘moderately satisfied’, 
‘slightly satisfied’, ‘neither’, ‘slightly dissatisfied’, ‘moderately dissatisfied’ and ‘very dissatisfied’.  
 
Putative Mediators and process variables:  
• Acceptance and Action Questionnaire (AAQ-II) (42) measures psychological flexibility, including 
experiential avoidance and psychological inflexibility. Each of the seven items are rated on a scale of 1-7, 
with higher scores representing greater experiential avoidance and immobility. 
 
• Mindfulness Attention Awareness Scale (MAAS) measures dispositional open awareness of and attention 
to the present moment (43). There are 15 items, each scored from 1-6. A mean of the 15 items is computed; 
with higher scores reflect higher levels of dispositional mindfulness. 
 
• Committed Action Scale (CAQ) measures committed action i.e. goal-directed, flexible persistence (44). 
Respondents rate the extent to which the 8 items apply to them from 0-6 with a greater total score 
representing a greater general propensity to persist in goal-directed behaviour  
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Qualitative component  
A nested qualitative study will explore patients’ experience of the ACT intervention. This will help identify 
factors that facilitate or impede adherence and acceptability of the treatment, and perhaps give insight into 
treatment mechanisms. Semi-structured interviews will be conducted post-intervention with approximately 
15 participants (purposively sampled to encompass a mix of gender, ages and symptom severity). 
Interviewers will use topic guides with open-ended questions and prompts to elicit participants’ accounts of 
their experiences. The interviews will be transcribed verbatim. Analysis will commence after the completion 
of the first interview in an iterative process to allow exploration of early insights in later interviews. Standard 
thematic analysis techniques will be applied (45), for example, coding the data and identifying themes that 
capture key concepts and processes. The results will supplement quantitative results and inform any future 
implementation of the intervention. 
 
Participant timeline  
Information is provided in the consort diagram (Figure 1) and the screening and data schedule of assessments 
(Table 2). The RA will contact potentially interested participants to ensure they are fully informed and 
eligible to take part in the trial. If this is the case, they will be asked to sign a consent form, enrolled onto the 
study, and provided with a unique identification number. The baseline assessments will be in person at one 
of the MD clinics with the RA and physiotherapist. Following baseline, the participant will be randomised 
and informed by the trial coordinator as to whether they will receive ACT plus SMC or SMC alone. The 
participant will complete follow-up measures at 3, 6 and 9 weeks online via an email link.   
 
Table 2 Screening and data collection across the trial: summary of key trial processes 
Process Screening  Baseline  3 week 6 week 9 week Ongoing or 
during trial  
Ref 
Eligibility  X      - 
Medical 
confirmation 
X      - 
HADs X X X X X  37 
MoCA X      28 
Participant 
details form 
 X     - 
INQoL  X X X X  33 
WSAS  X X X X  34 
HAQ-DI  X X X X  37 
IBM*  X X X X  38 
AAQ-II  X X X X  40 
MASS  X X X X  41 
CAQ  X X X X  42 
Health Events  X X X X  - 
ANA  X     31 
6MTWT  X     31 
MMST  X     32 
PGIC   X X X  39 
Satisfaction 
rating 
  X X X  - 
Safety events 
(e.g. AE, SAEs) 
     X     - 
Drop-out / 
withdrawal 
     X - 
Therapist ratings      X - 
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Sample size 
154 patients will be recruited in total, 77 per trial arm. This sample size will provide adequate power to 
detect a standardised mean difference of 0.5 (medium magnitude) in the primary outcome between the 
treatment and control groups at the end of intervention assessment (5% significance, 80% power), assuming 
attrition of 20%. Using data from Vincent et al., (35) this equates to between an 11.5 and 15.8 point 
difference on each of the INQOL domains. While no information is currently available regarding clinically 
important differences for the INQOL, an effect size of this magnitude typically relates to a clinically 
important difference for health related quality of life instruments (46). 
 
Recruitment  
Participants will be recruited from MD clinics, Muscular Dystrophy UK and MD registries. In MD clinics, 
consultants and physiotherapists will identify potentially eligible participants who will either be given an 
information pack consisting of an invitation letter, information sheet and reply slip to state their interest. MD 
UK and MD registries will advertise the study and provide invitation packs. When someone states their 
interest, the RA will call them to provide further information, answer any questions and conduct screening. If 
they are eligible for the study (including medical confirmation from their health professional) then the 
participant will sign a consent form before being enrolled into the study. 
 
Patient and Public Involvement 
Dr Rose’s direct work with patients within a MD clinic led to the development of the trial. In developing the 
study material, a small pilot study of the self-guided intervention was tested and subsequently refined in 
response to participants’ feedback by Dr Graham (Graham, 2012). Our patient representative has been 
actively involved at every stage from assessing the intervention to reviewing the outcome measures. 
Muscular Dystrophy UK (MD UK), a patient support organisation contributed to the development of the 
study and will help with the referral of patients into the study. MD UK will also be involved in disseminating 
study results. 
KEY 
HADS Hospital Anxiety and Depression Scale 
MOCA Montreal Cognitive Assessment 5-minute protocol 
INQOL Individualised Neuromuscular Quality of Life Questionnaire 
WSAS Work and Social Adjustment Scale 
HAQ-DI Stanford Health Assessment Questionnaire Disability Index 
IBM IBM Functional Rating Scale 
AAQ-II Acceptance and Action Questionnaire 
MASS Mindfulness Attention Awareness Scale 
CAQ Committed Action Questionnaire 
ANA Adult Ambulatory Neuromuscular Assessment 
6MTWT 6-minute timed walk test 
MMST Manual Muscle Strength Testing 
PGIC Patient Global Impression of Change scale 
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METHODS: ASSIGNMENT OF INTERVENTIONS 
Allocation  
Randomisation will be conducted by an independent randomisation service at the UK Clinical Research 
Collaboration registered at the King’s Clinical Trials Unit. Randomisation will be at the level of the 
individual, using block randomisation with randomly varying block sizes stratified by recruiting centre. 
Allocation confirmation will be generated automatically and sent to unblinded research members, including 
the trial co-ordinator and clinical psychologist. 
 
Allocation concealment 
A position of equipoise will be maintained but blinding of the patients and therapist to the treatment 
condition will not be possible. The RA contacting participants and inputting data will be blind to group 
allocation to reduce the risk of introducing bias. To protect against unblinding, all follow-up questionnaires 
will be completed by participants on Bristol Online Survey (BOS) which is specifically designed for 
academic research and fully compliant with UK data protection law. All questionnaires will be identical for 
both arms and designed not to reveal treatment allocation. The trial statistician will be blind to treatment 
group when conducting the main data analysis.   
 
METHODS: DATA COLLECTION, MANAGEMENT AND ANALYSIS 
 
Data collection Methods 
Baseline data will be collected prior to randomisation and consist of self-report questionnaires and objective 
assessments with the physiotherapist. Follow-up data (3, 6 & 9 weeks) include self-report questionnaires that 
will be completed remotely. At each follow-up point participants will be emailed a link to BOS along with 
their unique identification number. If participants are unwilling or unable to complete all the questionnaires 
they will be given the option of going through them on the phone or a reduced questionnaires pack with the 
primary outcomes (INQoL). 
 
Data Management  
All trial data will be stored in line with the Data Protection Act 1998 and in compliance with Good Clinical 
Practice and King’s College London data management procedures. Any identifying data will be anonymised 
through use of unique identification numbers separated from identifying data. Data will be entered onto 
password-protected trial databases either on a shared hard-drive accessible only to assigned team members or 
in a locked cabinet in a room only accessible to staff with designated access cards. All source documents will 
be retained for a period of 10 years following the end of the study. 
 
Statistical methods 
Statistical analyses of the primary and secondary outcomes will be conducted after the database has been 
locked, with no interim analyses. All analyses will adopt the intention to treat principle (ITT). The main 
statistical analyses will estimate the difference in mean outcomes between patients randomised to ACT plus 
SMC and SMC alone at the primary endpoint of 9 weeks and at the two other post-randomisation time 
points. Group difference estimates, associated confidence intervals and standardised effect sizes will be 
reported. Significance testing will be performed where the significance level will be 5% (2-sided). 
Sensitivity analyses will be used to assess the robustness of conclusions to missing outcome data using a 
pattern mixture model approach and to departures from randomised treatment in a per protocol analysis 
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excluding those not receiving. Loss to follow-up, departures from randomised treatment and the prevalence 
of serious adverse events will be reported. 
The primary outcome is the INQoL quality of life (QoL) score. Quality of life at all three post-randomisation 
time points (3, 6 and 9 weeks after randomisation) will be modelled simultaneously using a linear mixed-
effects model. A random intercept will account for the non-independence of observations across individuals. 
Trial arm and indicator coded time will be included as covariates along with arm by time interaction terms to 
allow the treatment effect to vary at each time point. Also, included in the model will be the baseline level of 
the QoL score and a stratification indicator variable for centre. Missing data at follow up assessments is 
allowed where at least one observation per participant is available under the missing at random assumption. 
Secondary patient outcomes (3, 6 and 9 weeks after randomisation) relating to symptom severity and 
functioning (WSAS; HAQ-DI), distress (HADS), impression of change (PGIC), and putative mediators of 
the intervention (CAQ; AAQ-II; MAAS) will be analysed using linear mixed-effects models. Random 
effects for the intercept and time will be included in the model.  
 
METHODS: MONITORING  
Data monitoring 
The study will be monitored and audited in accordance with King’s College Hospital NHS Foundation Trust 
and King’s College London procedures. All trial related documentation will be made available on request to 
the sponsors, HRA/ REC and other licencing bodies. Monitoring of this study to ensure compliance with 
Good Clinical Practice and scientific integrity will be managed by the study team and reviewed by an 
independent Trial Steering Committee (TSC) & Data Monitoring & Ethics Committee (DMEC).  
Harms/ Assessment of safety  
Adverse events will be recorded at baseline, 3, 6 and 9 weeks. We define adverse events as 'any clinical 
change, disease or disorder experienced by the participant during their participation in the trial, whether or 
not considered related to the use of treatments being studied in the trial’ (47). Adverse events will also 
include any other events that might have affected the health status of a participating patient (e.g. increased 
work stress).  
The team will also monitor serious adverse events (SAEs), serious adverse reactions (SAR), suspected 
unexpected serious adverse reactions (SUSAR) and active withdrawals from treatment. A SAE constitutes 
any adverse event or reaction that: results in death or a new persistent or new significant disability or 
incapacity, is life threatening or requires hospitalisation, any new episode of deliberate self-harm or any 
other important medical condition which may jeopardise the participant and require medical or surgical 
intervention to prevent one of the outcomes listed above. 
A serious adverse reaction (SAR) can be defined as a SAE as a reaction to the intervention. A SUSAR is any 
serious adverse reaction that is suspected to be caused by the intervention but was not expected. All SAEs, 
SARs and SUSARs will be reported immediately by the Chief Investigator to the study Sponsor and 
Research Ethics Committee. The TSC-DMEC will be responsible for the independent investigation of SAEs.  
 
ETHICS AND DISSEMINATION  
Research ethics approval 
The trial is subject to Health Research Authority (HRA) approval that brings together the assessment of 
governance and legal compliance with the independent Research Ethics Committee (REC) approval. The 
trial has ethical approval by London - Camberwell St Giles REC (16/LO/0609). Site-specific confirmation of 
capacity and capability has been given by local research and development departments. The study will 
comply with the principles of the Declaration of Helsinki (1996) (48), the International Conference for 
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Harmonisation of Good Clinical Practice (ICH GCP; (49)) guidelines and the Research Governance 
Framework for Health and Social Care 2nd Edition (2005). The trial is sponsored by King’s College Hospital 
NHS Foundation Trust (lead) and King’s College London and has been registered onto a publicly accessible 
database (Registration number: NCT02810028). 
Consent 
Inclusion in the trial is appropriate only if potential participants are aged 18 or older and are able to give 
written informed consent. All potentially eligible participants will be fully informed about the study 
procedures by a participant information sheet that states participation is voluntary and that they are free to 
withdraw from the study at any time without giving a reason and without their care being affected.   
Declaration of interests 
The authors declare that they have no competing interests. 
Dissemination 
Summaries of findings will be offered to MD charities, registries, and support groups as well as to the wider 
public. The results of the trial will be communicated to participants via a newsletter. Any results from the 
trial will enable informed decisions regarding the provision of care for patients with MD. 
 
CONCLUSION  
Experiences of psychological distress and reduced QoL are common in people with MD. A brief, guided 
self-help ACT intervention with telephone support sessions has been designed for remote delivery, offering a 
potential solution to mobility issues inherent with MD and under-resourced healthcare services. This is the 
first study to evaluate whether ACT can help improve QoL for individuals with MD. It will also be one of 
the largest randomised controlled trials of ACT for improving outcomes in long-term conditions. If the 
intervention proves to be efficacious, this treatment delivery could facilitate participation for those 
individuals whose impaired mobility prevents travelling to face-to-face sessions. As the main barrier to the 
adoption of any psychological intervention is the paucity of psychological services, the ACT intervention has 
been designed to be a self-guided programme requiring minimal support from highly qualified professionals.  
 
Abbreviations: 
ACT: Acceptance and Commitment Therapy, MD: Muscle Disease, SMC: Standard Medical Care QoL: 
Quality of Life, HRA: Health Research Authority, REC: Research Ethics Committee, AE: Adverse Event, 
SAE: Serious Adverse Event, SAR: Serious Adverse Reaction, SUSAR: Suspected Unexpected Serious 
Adverse Reaction, TSC-DMEC: Trial Steering Committee / Data Monitoring & Ethics Committee, PPI: 
patient and public involvement.  
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Figure 1 Consort Diagram for ACTMuS 
 
 
 
 
